<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02003989</url>
  </required_header>
  <id_info>
    <org_study_id>RBM_CLL_2012-7</org_study_id>
    <nct_id>NCT02003989</nct_id>
  </id_info>
  <brief_title>Revealing Increased Axonal Loss in Treated HIV Patients</brief_title>
  <acronym>OCTIHIV</acronym>
  <official_title>Revealing Increased Axonal Loss in Treated HIV Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HIV patients may suffer sooner from aging than average population, including brain aging. Our
      hypothesis is that if brain dysfunctions are explained by a quicker loss of neurons in HIV
      patients, this loss could be detected earlier by a thinning down of retinal nerve fiber layer
      (RNFL), compared to non HIV patients of the same age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators aim to compare the thickness of the RNFL and the thickness of the RCGs
      measured by spectral domain OCT between patients infected by HIV and patients of same age non
      infected by HIV.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>thickness of the RNFL and the RCGs measured by spectral domain OCT, between the two groups of patients</measure>
    <time_frame>one day of examinations</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">156</enrollment>
  <condition>HIV Seropositivity</condition>
  <arm_group>
    <arm_group_label>patients</arm_group_label>
    <description>HIV patients infected for more than ten years with undetectable viral load, undergoing ophthalmologic examination and MRI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <description>non HIV patients (same gender and age) undergoing ophthalmologic examination and MRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ophthalmologic examination and MRI</intervention_name>
    <description>thorough investigation of patients, not included in usual care.</description>
    <arm_group_label>patients</arm_group_label>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        HIV patients infected for at least 10 years with undetectable viral load, selected among
        infectious disease outpatients (consecutive exhaustive recruitment)

        non HIV patients matched for age and gender
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV infection known since at least 10 years

          -  viral load undetectable under ARV treatment since at least 5 years, whatever the type
             of ARV

          -  lymphocytes CD4 &gt; 350, whatever the CD4 nadir

          -  signed informed consent

        Exclusion Criteria:

          -  History of ocular pathology, eye surgery, or intraocular injection

          -  Familial History of glaucoma

          -  ametropia (&gt;3 dioptres on the sphere and &gt;1,5 dioptres on the cylinder)

          -  known neurological pathology, active or former

          -  History of ethambutol or synthetic antimalarial drug consumption

          -  History of chemotherapy

          -  Active and regular use of drugs

          -  non-weaned chronic alcoholism

          -  contra indication to MRI

          -  diabetes

          -  cognitive disorders (MoCA&lt;26)

          -  non covered by health insurance

          -  patient under legal protection

          -  pregnant or breast-feeding woman

          -  Non inclusion criteria for control patients: known HIV infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CÃ©dric LAMIREL, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondation Ophtalmologique Adolphe de Rothschild</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe GIRARD, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Mutualiste Montsouris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antoine MOULIGNIE, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondation Ophtalmologique Adolphe de Rothschild</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fondation OPH A de Rothschild</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2013</study_first_submitted>
  <study_first_submitted_qc>December 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2013</study_first_posted>
  <last_update_submitted>October 20, 2016</last_update_submitted>
  <last_update_submitted_qc>October 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Seropositivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

